An ECI Conference
Registration coming soon
May 1-4, 2022
Boulder, Colorado
Abstract Submission
About This Conference
It is well known that the physical and chemical properties of the DS (API) have major impacts on the formulation and the Drug Product (DP) process. In any dosage form including solid, liquid and semi-solid, the Drug Substance (DS) or Active Pharmaceutical Ingredient (API) goes through a formulation process. This process to make the final drug product serves many purposes, but all with the goal of eventually delivering the active ingredient to the desired sites in the patients’ body in the most convenient way and to achieve optimal therapeutic effect.
For most small molecule drugs, the final step in an arduous synthetic sequence is usually the crystallization or precipitation of the DS. This serves as both an isolation as well as purification step. In addition, many particle engineering techniques have been advanced that can tailor the physical and chemical properties of the drug substance during the final step in order to facilitate the design and scaleup of a rugged and reproducible DP processes. From historical and regulatory viewpoints, the blurring of the DS/DP interface while having the potential to offer competitive advantages, there will be regulatory and cultural hurdles that need to be ameliorated. The impact of DS properties on DP performance and the DP processes have attracted wide interest in the industry. However, many engineering issues and mechanistic understanding concerning the DS, the formulation, and their interface still need to be developed and explored. This conference seeks to bring scientists, engineers and regulators working at this critical interface for mutual discussion of current results, future improvement and to identify any technical and regulatory needs that still exist. Participants attending this conference will significantly benefit from learning the innovations from the integration of DS (API) and the formulation of the drug product.
Conference Program Themes
- Role of particle engineering
- Material science of API/DS and formulation -Impact on drug product performance and process scaleup
- Pharmaceutical composite materials
Conference Program
Program coming soon
Conference Organization
Conference Chair
San Kiang, Porton Pharmatech Co. Ltd.
Conference Co-Chairs
Kaushalendra Chaturvedi, J-Star Research
Tianyi Li, J-Star Research
Organizing Committee
- Deniz Erdemir, BMS, USA
- Mauricio Futran, Janssen, USA
- Junbo Gong, Tianjin University, China
- Ren Guobin, East China University of Science and Technology, China
- Soojin Kim, Hanmi Pharmaceutical Co., South Korea
- Alfred Lee, Merck & Company Inc., USA
- Allan Myerson, Massachusetts Institute of Technology, USA
- Srividya Ramakrishnan, Dr. Reddy’s Laboratories, India
- Vidya Swaminathan, AstraZeneca, UK
- Bing-Shiou Yang, Boehringer Ingelheim Pharmaceuticals, Inc., USA
Invited Speakers
Material Science Session
Simon J. L. Billinge
Professor of Materials Science and Engineering and Applied Physics and Applied Mathematics, Columbia University
Research Areas:
Amorphous and nanostructured pharmaceuticals and molecular materials, methods for solving the nanostructure problem, nanoscale fluctuations in exotic electronic materials, nanostructured materials for energy and environmental remediation, software for complex modeling and nanostructure determination
Title of Presentation:
Advanced X-Ray Analysis of Disordered and Composite Materials
Boris Rybtchinski
Associate Professor, Department of Organic Chemistry Weizmann Institute of Science
Research Areas:
Supramolecular chemistry, crystallization mechanisms, sustainable and energy materials, as well as electron microscopy
Title of Presentation:
Imaging Organic and Protein Crystallization Mechanisms
Clare Strachan
Associate Professor, School of Pharmacy University of Helsinki
Research Areas:
The physicochemical characterisation and optimisation of solid drugs and dosage forms
Title of Presentation:
Application of Non-Linear Imaging and Spectroscopy to Engineered Particles
Christian Serre
Research Director, Centre National de la Recherche Scientifique
Organization: Institut des Matériaux Poreux de Paris
Research Areas:
Synthesis, structure determination, including the use of X-ray diffraction data, and applications related to health, environment and energy of porous stable and functional porous solids (Metal Organic frameworks…)
Title of Presentation:
Porous Biocompatible Metal Organic Frameworks in Biomedicine
David Lechuga-Ballesteros
Research Fellow PT&D, Inhalation Product Development
Organization: AstraZeneca Pharmaceuticals LP
Research Areas:
Pharmaceutical materials science
Title of Presentation:
The Relevance of Pharmaceutical Material Sciences in the Development of Inhaled Biologics
Sven L. M. Schroeder
Professor, Leeds University
Research Areas:
nanoscience; analytical science; physical chemistry; surfaces; crystallisation; catalysis; wastewater; formulation; interfaces; colloids; synchrotron radiation; X-ray; spectroscopy; microscopy
Title of Presentation:
MONITORING OF CRYSTALLIZATION PROCESSES WITH REAL-TIME X-RAY PHASE-CONTRAST IMAGING (XPCI) AND COMPLEMENTARY ADVANCED X-RAY ANALYSIS
Particle Technology Session
Christopher Burcham
Senior Engineering Advisor, Eli Lilly and Company
Research Areas:
Pharmaceutical Process Development with an emphasis on Crystallization and particle formation process design; mechanistic modeling
Title of Presentation:
Examples of Particle Engineering to Improve Patient Outcomes and Product Manufacturing
Marco Mazzotti
Prof. Dr. Dr. h.c., ETH Zurich
Research Areas:
Crystallization, Carbon Dioxide Capture and Storage systems
Title of Presentation:
SIZE AND SHAPE ENGINEERING OF NEEDLE-LIKE CRYSTALS
Allan S. Myerson
Professor, Massachusetts Institute of Technology
Research Areas:
Crystallization, pharmaceutical manufacturing
Title of Presentation:
CONTINUOUS CRYSTALLIZATION AND PURIFICATION: THE ROLE OF IMPURITY INCORPORATION MECHANISMS IN NON-EQUILIBRIUM PROCESSES
Zoltan K Nagy
Professor of Chemical Engineering, Purdue University
Research Areas:
Crystallization and particulate systems engineering, Process Systems Engineering, Process Intensification and Control, Advanced pharmaceutical manufacturing
Title of Presentation:
Novel Process Intensification Approaches to Integrate Drug Substance and Drug Product Manufacturing
Jian Wang
VP, Center for Pharma Crystallization, J-Star Research, Inc.
Research Areas:
Crystallization Process R&D
Polymorph Discovery & Studies
Pre/Early Formulation Evaluation
DS-DP Co-Processing
Title of Presentation:
Bridging the Gap between API and Drug Product via Coprocessing
Dr. Fredrik L. Nordstrom
Senior Research Fellow, Boehringer Ingelheim
Research Areas:
Isolation development, polymorphism and impurity purge mechanisms relevant to pharmaceutical applications
Title of Presentation:
Root-cause analysis across the DS-DP interface in the pharmaceutical development and manufacturing
Composite Material Session
Deniz Erdemir
Principal Scientist, Bristol-Myers Squibb
Research Areas:
Dr. Erdemir’s research focus lies at the drug substance-drug product interface with emphasis on crystal polymorphism and design of materials via particle engineering to enable robust drug products
Title of Presentation:
CO-PROCESSING METHODOLOGIES TO IMPROVE POWDER PROPERTIES OF DRUG SUBSTANCES
Saif A. Khan
Associate Professor, Chemical and Biomolecular Engineering, National University of Singapore
Research Areas:
Continuous Pharmaceutical and Materials Manufacturing, Microfluidics, Flow Chemistry, Particle Engineering
Title of Presentation:
DRUG PARTICLE ENGINEERING USING MICROFLUIDIC EMULSION-BASED CRYSTALLIZATION
Korbinian Löbmann
Associate Professor, University of Copenhagen
Research Areas:
My research background lies in solid drug formulation and physico-chemical characterization thereof. This includes in particular the development of new enabling formulation strategies, such as amorphous solid dispersions containing proteins as stabilizers, co-amorphous drug delivery systems, and microwave amorphization (in situ amorphization); as well as novel excipients, such as mesoporous silica or cellulose nanofibers
Title of Presentation:
Co-amorphous systems and multicomponent amorphous mixtures
Changquan Calvin Sun
Director of Graduate Studies, Professor, Department of Pharmaceutics, University of Minnesota
Research Areas:
Pharmaceutical Materials Science, Powder Technology, Solid-state Science, Crystal engineering
Title of Presentation:
Challenges and opportunities in optimizing mechanical properties of drugs by incorporating excipients
Rajesh N Davé
Distinguished Professor, Ph.D. , New Jersey Institute of Technology
Research Areas:
Particle Engineering, direct compression formulations, engineered excipients, drug nano-composites, polymer film coating of fine particles, dry coating, thin films for pediatric/geriatric drug delivery
Title of Presentation:
Predictively Enhancing Bulk Properties of Cohesive Pharmaceutical Powders
Patrick Doyle
Robert T. Haslam, Professor of Chemical Engineering, MIT
Research Areas:
Microfluidics, soft matter, biophysics
Title of Presentation:
New API formulations enabled by soft matter concepts
Special Topic Session
Huiquan Wu, Research Chemical Engineer, Division of Manufacturing Assessment I (DMA I), Office of Pharmaceutical Manufacturing Assessment (OPMA), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA)
Research Areas
Pharmaceutical Manufacturing Process Understanding and In-Process Control, Process Analytical Technology (PAT) and its Pharmaceutical Applications, Manufacturing Process Engineering and Integration Assessment
Title of Presentation
Critical Pharmaceutical Manufacturing Process Challenges and Opportunities with Illustrations from Scientific Research Case Studies
Abstract Submission
The abstracts should be submitted as soon as possible and no later than the deadlines noted below. The abstract should consist of 5 parts: purpose, method, results, conclusion, and reference. The abstract should introduce the proposed paper’s subject, summarize its contents, explain any unique aspects, and clearly indicate the specific relevance to the themes of the Conference. The abstract must be at least half a page in length with a two page maximum.
Announcement coming soon for long & short oral presentations and poster presentation.
Please prepare your abstract according to this template: docx or doc.
All abstracts should be submitted electronically. [Coming Soon]
Only a limited number of oral presentation slots are available and thus all submissions for oral sessions will be considered for both oral and poster presentation.
All accepted abstracts will be published as a proceeding before the conference.
Conference Sponsors
Sponsorship Levels
General Information about ECI
Engineering Conferences International (ECI) is a not-for-profit, global engineering conferences program, originally established in 1962 that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.
The format of the conference provides morning and late afternoon or evening sessions in which major presentations are made. Poster sessions will be scheduled for evening discussion as well. Available time is included during the afternoons for ad hoc meetings, informal discussions, and/or recreation. This format is designed to enhance rapport among participants and promote dialogue on the development of the meeting. We believe the conferences have been instrumental in generating ideas and disseminating information to a greater extent than is possible through more conventional forums.
All participants are expected both to attend the entire conference and to contribute actively to the discussions. The recording/photographing of lectures and presentations is forbidden. As ECI conferences take place in an informal atmosphere, casual clothing is the usual attire.
Smoking is prohibited at ECI conferences and conference functions.